CORT Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of 25.86% compared to Corcept Therapeutics's net margin of -22.27%. Corcept Therapeutics's return on equity of 25.77% beat Alnylam Pharmaceuticals's return on equity of --.

Corcept Therapeutics has a consensus price target of --, signalling upside risk potential of 43.57%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $299.11 which suggests that it could grow by 22.96%. Given that Corcept Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Alnylam Pharmaceuticals.

Corcept Therapeutics has a beta of 0.513, which suggesting that the stock is 48.73% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.319, suggesting its less volatile than the S&P 500 by 68.077%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $182.5M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $500.9M. Corcept Therapeutics's net income of $47.2M is higher than Alnylam Pharmaceuticals's net income of -$111.6M. Notably, Corcept Therapeutics's price-to-earnings ratio is 41.40x while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 9.25x versus 14.72x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 25.86% compared to Corcept Therapeutics's net margin of 34.1%. Corcept Therapeutics's return on equity of 25.77% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Corcept Therapeutics has a consensus price target of --, signalling upside risk potential of 43.57%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 49.17%. Given that Catalyst Pharmaceuticals has higher upside potential than Corcept Therapeutics, analysts believe Catalyst Pharmaceuticals is more attractive than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.513, which suggesting that the stock is 48.73% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.748, suggesting its less volatile than the S&P 500 by 25.213%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $182.5M, which are larger than Catalyst Pharmaceuticals quarterly revenues of $128.7M. Corcept Therapeutics's net income of $47.2M is higher than Catalyst Pharmaceuticals's net income of $43.9M. Notably, Corcept Therapeutics's price-to-earnings ratio is 41.40x while Catalyst Pharmaceuticals's PE ratio is 18.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 9.25x versus 5.72x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of 25.86% compared to Corcept Therapeutics's net margin of -104.98%. Corcept Therapeutics's return on equity of 25.77% beat Ionis Pharmaceuticals's return on equity of -93.21%.

Corcept Therapeutics has a consensus price target of --, signalling upside risk potential of 43.57%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.36 which suggests that it could grow by 67.97%. Given that Ionis Pharmaceuticals has higher upside potential than Corcept Therapeutics, analysts believe Ionis Pharmaceuticals is more attractive than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.513, which suggesting that the stock is 48.73% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.148%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $182.5M, which are larger than Ionis Pharmaceuticals quarterly revenues of $133.8M. Corcept Therapeutics's net income of $47.2M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Corcept Therapeutics's price-to-earnings ratio is 41.40x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 9.25x versus 6.64x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of 25.86% compared to Corcept Therapeutics's net margin of -172.04%. Corcept Therapeutics's return on equity of 25.77% beat Madrigal Pharmaceuticals's return on equity of -89.04%.

Corcept Therapeutics has a consensus price target of --, signalling upside risk potential of 43.57%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 19.55%. Given that Corcept Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Madrigal Pharmaceuticals.

Corcept Therapeutics has a beta of 0.513, which suggesting that the stock is 48.73% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.418, suggesting its less volatile than the S&P 500 by 141.819%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $182.5M, which are larger than Madrigal Pharmaceuticals quarterly revenues of $62.2M. Corcept Therapeutics's net income of $47.2M is higher than Madrigal Pharmaceuticals's net income of -$107M. Notably, Corcept Therapeutics's price-to-earnings ratio is 41.40x while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 9.25x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.